{"id":742209,"date":"2012-06-15T16:05:00","date_gmt":"2012-06-15T16:05:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/u-s-district-court-rules-against-merck-in-nasonex-mometasone-furoate-monohydrate-patent-lawsuit\/"},"modified":"2023-03-22T00:04:23","modified_gmt":"2023-03-22T04:04:23","slug":"u-s-district-court-rules-against-merck-in-nasonex-mometasone-furoate-monohydrate-patent-lawsuit","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/u-s-district-court-rules-against-merck-in-nasonex-mometasone-furoate-monohydrate-patent-lawsuit\/","title":{"rendered":"U.S. District Court Rules Against Merck in NASONEX\u00ae (mometasone furoate monohydrate) Patent Lawsuit"},"content":{"rendered":"<p class=\"bwalignl\">\n      Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      announced today that the U.S. District Court for the District of New<br \/>\n      Jersey ruled against the company in a patent infringement suit against<br \/>\n      Apotex Inc. and Apotex Corp.\n    <\/p>\n<p>\n      &#8220;While we are pleased with the court&#8217;s ruling that the patent for<br \/>\n      NASONEX is valid, we are disappointed the court ruled that this patent<br \/>\n      would not be infringed by the Apotex product. We believe the patent for<br \/>\n      NASONEX in the United States is valid and would be infringed by the<br \/>\n      Apotex product,&#8221; said Bruce N. Kuhlik, executive vice president and<br \/>\n      general counsel of Merck. &#8220;Today&#8217;s decision reflects just one step in<br \/>\n      the lengthy patent litigation process, and we plan to review all of our<br \/>\n      options, including a likely appeal of the decision.&#8221;\n    <\/p>\n<p>\n      The patent at issue in this case is U.S. Patent No. 6,127,353 that<br \/>\n      covers mometasone furoate monohydrate, the active ingredient in NASONEX<br \/>\n      and which provides exclusivity for this form of mometasone until April<br \/>\n      3, 2018.\n    <\/p>\n<p>\n      Apotex is seeking U.S. Food and Drug Administration (FDA) approval to<br \/>\n      sell a generic version of NASONEX.\n    <\/p>\n<p>\n      Judge Peter G. Sheridan presided over the trial. Merck was represented<br \/>\n      by the law firms Weil, Gotshal &#038; Manges LLP and Gibbons P.C.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\"><span class=\"bwuline\">vip2-msd.com\/merckcom-migrated<\/span><\/a><span class=\"bwuline\"><br \/>\n      <\/span>and connect with us on Twitter, Facebook and YouTube.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. Such statements may include,<br \/>\n      but are not limited to, statements about the benefits of the merger<br \/>\n      between Merck and Schering-Plough, including future financial and<br \/>\n      operating results, the combined company\u2019s plans, objectives,<br \/>\n      expectations and intentions and other statements that are not historical<br \/>\n      facts. Such statements are based upon the current beliefs and<br \/>\n      expectations of Merck\u2019s management and are subject to significant risks<br \/>\n      and uncertainties. Actual results may differ from those set forth in the<br \/>\n      forward-looking statements.\n    <\/p>\n<p>\n      The following factors, among others, could cause actual results to<br \/>\n      differ from those set forth in the forward-looking statements: the<br \/>\n      possibility that the expected synergies from the merger of Merck and<br \/>\n      Schering-Plough will not be realized, or will not be realized within the<br \/>\n      expected time period; the impact of pharmaceutical industry regulation<br \/>\n      and health care legislation; the risk that the businesses will not be<br \/>\n      integrated successfully; disruption from the merger making it more<br \/>\n      difficult to maintain business and operational relationships; Merck\u2019s<br \/>\n      ability to accurately predict future market conditions; dependence on<br \/>\n      the effectiveness of Merck\u2019s patents and other protections for<br \/>\n      innovative products; the risk of new and changing regulation and health<br \/>\n      policies in the U.S. and internationally and the exposure to litigation<br \/>\n      and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2011 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/www.sec.gov\"><span class=\"bwuline\">www.sec.gov<\/span><\/a>).\n    <\/p>\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&#038;sty=20120615005993r1&#038;sid=sfsite1&#038;distro=nx\" \/><span class=\"bwct31415\"\/><\/span><\/p>\n<p>       Merck<br \/>Media Contact: Ron Rogers, (908) 423-6449<br \/>Investor        Contact: Carol Ferguson, (908) 423-4465     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. District Court for the District of New Jersey ruled against the company in a patent infringement suit against Apotex Inc. and Apotex Corp. &#8220;While we are pleased with the court&#8217;s ruling that the patent for NASONEX is valid, we are disappointed the court ruled that this patent would not be infringed by the Apotex product. We believe the patent for NASONEX in the United States is valid and would be infringed by the Apotex product,&#8221; said Bruce N. Kuhlik, executive vice president and general counsel of Merck. &#8220;Today&#8217;s decision reflects just one step in the lengthy patent litigation process, and we plan to review all of our options, including a likely appeal of the decision.&#8221; The patent at issue in this case is U.S. Patent No. 6,127,353 that covers mometasone furoate monohydrate, the active ingredient in NASONEX and which provides exclusivity for this form of mometasone until April 3, 2018.<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,289],"class_list":["post-742209","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>U.S. District Court Rules Against Merck in NASONEX\u00ae (mometasone furoate monohydrate) Patent Lawsuit - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/u-s-district-court-rules-against-merck-in-nasonex-mometasone-furoate-monohydrate-patent-lawsuit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"U.S. District Court Rules Against Merck in NASONEX\u00ae (mometasone furoate monohydrate) Patent Lawsuit - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. District Court for the District of New Jersey ruled against the company in a patent infringement suit against Apotex Inc. and Apotex Corp. &quot;While we are pleased with the court&#039;s ruling that the patent for NASONEX is valid, we are disappointed the court ruled that this patent would not be infringed by the Apotex product. We believe the patent for NASONEX in the United States is valid and would be infringed by the Apotex product,&quot; said Bruce N. Kuhlik, executive vice president and general counsel of Merck. &quot;Today&#039;s decision reflects just one step in the lengthy patent litigation process, and we plan to review all of our options, including a likely appeal of the decision.&quot; The patent at issue in this case is U.S. Patent No. 6,127,353 that covers mometasone furoate monohydrate, the active ingredient in NASONEX and which provides exclusivity for this form of mometasone until April 3, 2018.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/u-s-district-court-rules-against-merck-in-nasonex-mometasone-furoate-monohydrate-patent-lawsuit\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:23+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20120615005993r1&sid=sfsite1&distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/u-s-district-court-rules-against-merck-in-nasonex-mometasone-furoate-monohydrate-patent-lawsuit\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/u-s-district-court-rules-against-merck-in-nasonex-mometasone-furoate-monohydrate-patent-lawsuit\\\/\",\"name\":\"U.S. District Court Rules Against Merck in NASONEX\u00ae (mometasone furoate monohydrate) Patent Lawsuit - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/u-s-district-court-rules-against-merck-in-nasonex-mometasone-furoate-monohydrate-patent-lawsuit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/u-s-district-court-rules-against-merck-in-nasonex-mometasone-furoate-monohydrate-patent-lawsuit\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20120615005993r1&sid=sfsite1&distro=nx\",\"datePublished\":\"2012-06-15T16:05:00+00:00\",\"dateModified\":\"2023-03-22T04:04:23+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/u-s-district-court-rules-against-merck-in-nasonex-mometasone-furoate-monohydrate-patent-lawsuit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/u-s-district-court-rules-against-merck-in-nasonex-mometasone-furoate-monohydrate-patent-lawsuit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/u-s-district-court-rules-against-merck-in-nasonex-mometasone-furoate-monohydrate-patent-lawsuit\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20120615005993r1&sid=sfsite1&distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20120615005993r1&sid=sfsite1&distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/u-s-district-court-rules-against-merck-in-nasonex-mometasone-furoate-monohydrate-patent-lawsuit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"U.S. District Court Rules Against Merck in NASONEX\u00ae (mometasone furoate monohydrate) Patent Lawsuit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"U.S. District Court Rules Against Merck in NASONEX\u00ae (mometasone furoate monohydrate) Patent Lawsuit - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/u-s-district-court-rules-against-merck-in-nasonex-mometasone-furoate-monohydrate-patent-lawsuit\/","og_locale":"en_US","og_type":"article","og_title":"U.S. District Court Rules Against Merck in NASONEX\u00ae (mometasone furoate monohydrate) Patent Lawsuit - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. District Court for the District of New Jersey ruled against the company in a patent infringement suit against Apotex Inc. and Apotex Corp. \"While we are pleased with the court's ruling that the patent for NASONEX is valid, we are disappointed the court ruled that this patent would not be infringed by the Apotex product. We believe the patent for NASONEX in the United States is valid and would be infringed by the Apotex product,\" said Bruce N. Kuhlik, executive vice president and general counsel of Merck. \"Today's decision reflects just one step in the lengthy patent litigation process, and we plan to review all of our options, including a likely appeal of the decision.\" The patent at issue in this case is U.S. Patent No. 6,127,353 that covers mometasone furoate monohydrate, the active ingredient in NASONEX and which provides exclusivity for this form of mometasone until April 3, 2018.","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/u-s-district-court-rules-against-merck-in-nasonex-mometasone-furoate-monohydrate-patent-lawsuit\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:23+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20120615005993r1&sid=sfsite1&distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/u-s-district-court-rules-against-merck-in-nasonex-mometasone-furoate-monohydrate-patent-lawsuit\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/u-s-district-court-rules-against-merck-in-nasonex-mometasone-furoate-monohydrate-patent-lawsuit\/","name":"U.S. District Court Rules Against Merck in NASONEX\u00ae (mometasone furoate monohydrate) Patent Lawsuit - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/u-s-district-court-rules-against-merck-in-nasonex-mometasone-furoate-monohydrate-patent-lawsuit\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/u-s-district-court-rules-against-merck-in-nasonex-mometasone-furoate-monohydrate-patent-lawsuit\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20120615005993r1&sid=sfsite1&distro=nx","datePublished":"2012-06-15T16:05:00+00:00","dateModified":"2023-03-22T04:04:23+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/u-s-district-court-rules-against-merck-in-nasonex-mometasone-furoate-monohydrate-patent-lawsuit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/u-s-district-court-rules-against-merck-in-nasonex-mometasone-furoate-monohydrate-patent-lawsuit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/u-s-district-court-rules-against-merck-in-nasonex-mometasone-furoate-monohydrate-patent-lawsuit\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20120615005993r1&sid=sfsite1&distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20120615005993r1&sid=sfsite1&distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/u-s-district-court-rules-against-merck-in-nasonex-mometasone-furoate-monohydrate-patent-lawsuit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"U.S. District Court Rules Against Merck in NASONEX\u00ae (mometasone furoate monohydrate) Patent Lawsuit"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"cfd12daa-7d62-4fcd-95b9-c97755100496","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742209","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742209\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742209"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742209"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}